STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Healthcare Biotechnology
drugs-5

Future Directions in Obesity Treatment: Survey Insights and Innovations

byLuca Blaumann
July 15, 2024
in Biotechnology, Mid-Cap, Pharmaceuticals
Reading Time: 4 mins read
Share on TwitterShare on LinkedIn

Exploring New Frontiers in Effective Weight Management

Obesity continues to be a pressing global health issue, necessitating the continual evolution of treatment strategies. A recent survey involving 30 healthcare professionals, comprising 14 endocrinologists and 16 obesity specialists, sheds light on current satisfaction levels with existing obesity treatments and underscores the critical areas requiring enhancement. This article delves into the survey findings and discusses the potential of emerging therapies such as AMGN’s MariTide (AMG 133) and VKTX’s VK2735 to address identified gaps in the obesity treatment landscape.

Key Findings from the Survey

The survey highlights that while the satisfaction with current obesity treatments remains reasonable, there is significant room for improvement. The primary areas identified for enhancement include:

  1. Access and Availability: Ensuring that treatments are easily accessible to a broader patient population.
  2. Oral and Less Frequent Dosing: The preference for oral medications and treatments that require less frequent dosing is evident, suggesting a need for more convenient administration methods.
  3. Additional Benefits Beyond Obesity: There is a strong demand for treatments that not only promote weight loss but also preserve lean muscle mass and offer other health benefits.

Challenges in Current Obesity Treatments

One of the major concerns identified is the high rate of treatment discontinuation. The survey reveals that affordability and tolerability are the main drivers of discontinuation, highlighting a critical barrier to effective long-term obesity management. Additionally, the lack of reimbursement for GLP-1 drugs and the financial burden on patients further exacerbate the issue.

Addressing Treatment Discontinuation and Side Effects

Given the significant discontinuation rates related to the intolerability of GLP-1 drugs, the survey explores various approaches to managing side effects. Dose reduction emerges as the leading strategy, emphasizing the need for tailored treatment plans to enhance patient adherence. Maintaining patients on therapy is crucial to mitigate the risk of obesity-related diseases, particularly cardiovascular disease, type 2 diabetes, and heart failure.

Future Clinical Updates and Physician Expectations

Physicians express a keen interest in long-term efficacy and safety in future clinical updates, particularly for subcutaneous VK2735 and MariTide. Additionally, there is a call for more information on the mechanism of action and the durability of weight loss after discontinuation. These insights align with previously reported findings, indicating that:

  1. At least 30% of patients discontinue GLP-1 therapy within a year.
  2. GLP-1 drugs are poorly reimbursed, posing financial challenges for patients.
  3. Some physicians are reluctant to prescribe GLP-1 drugs due to concerns about patient tolerability and affordability.

The Importance of Preserving Lean Muscle Mass

The survey underscores that not all weight loss is created equal. The loss of lean muscle mass, often associated with negative outcomes, is a significant concern. Weight cycling, or the repeated loss and regain of weight, exacerbates the risk of low muscle mass. Since the loss of lean muscle mass can undermine the health benefits of weight loss, future obesity treatments must prioritize adherence to therapy and the preservation of lean muscle mass.

Advancements in Body Composition Monitoring

The survey anticipates that both physicians and patients will become increasingly familiar with fat distribution and body composition as advanced imaging techniques become more widely used. This trend is seen as favorable for AMGN’s MariTide, which may benefit from this growing awareness.

The Promise of Rx to OTC Switches

The ultimate opportunity in obesity treatment may lie in the development of a drug that can transition from prescription (Rx) to over-the-counter (OTC) status. The FDA’s guidance on such switches emphasizes the need for drugs that are safe, effective, and easily self-administered, with patients capable of monitoring their own treatment. VKTX’s oral VK2735 is seen as a potential candidate meeting these criteria, extending the product lifecycle beyond patent expiry.

Conclusion: A Path Forward in Obesity Treatment

The survey findings provide a comprehensive overview of the current challenges and opportunities in obesity treatment. As new therapies like AMGN’s MariTide and VKTX’s VK2735 emerge, there is hope for more effective, accessible, and convenient treatment options. By addressing key areas such as affordability, tolerability, and the preservation of lean muscle mass, the future of obesity treatment looks promising. Continued innovation and patient-centered approaches will be crucial in advancing the fight against obesity and improving overall health outcomes.

You might like this article:Goldman Sachs Reports a 150% Surge in Q2 Profits Amid Investment Banking Revival

Tags: analystBreakingGLP-1GrowthMoversNewsweightloss
Previous Post

Goldman Sachs Reports a 150% Surge in Q2 Profits Amid Investment Banking Revival

Next Post

Macy’s Embarks on Solo Turnaround Plan After Calling Off Investor Buyout

Related Posts

chemistry-2

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

byLiliana Vida
November 17, 2026
0

Pivotal REGAL trial demonstrates significant survival benefits, positioning the company for a potential FDA submission in 2027. SELLAS Life Sciences...

D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

byLiliana Vida
November 11, 2026
0

Quantum computing company reports $4.5 million in revenue, strong year-to-date bookings, and potential access to $100 million in federal funding....

investing

D-Wave Quantum Q3 Revenue Rises 21% as Bookings Surge and Quantum Adoption Expands

byLuca Blaumann
November 10, 2026
0

Quantum computing company beats earnings expectations, reports $503 million in liquidity, and advances major technology initiatives across global markets. D-Wave...

Next Post
macy's-storefront

Macy's Embarks on Solo Turnaround Plan After Calling Off Investor Buyout

Latest News

Anthropic Leveraged ETFs: What GraniteShares’ AIL and ANS Offer Traders

KULR Technology Secures $14.8 Million Purchase Order for Advanced Energy Storage Systems

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers

D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

Based on Your Interest

Artificial Intelligence

CoreWeave Q3 Revenue Surges Nearly 170% to $3.66 Billion as AI Demand Accelerates

November 11, 2026
Artificial Intelligence

CoreWeave Earnings Preview: Why Guidance Matters More Than Q3 Results

November 10, 2026
investing
Artificial Intelligence

D-Wave Quantum Q3 Revenue Rises 21% as Bookings Surge and Quantum Adoption Expands

November 10, 2026

Recommended

Auto Manufacturers

Lucid Secures $1.75 Billion Liquidity Boost From Saudi PIF to Support Turnaround

November 10, 2026
Artificial Intelligence

KULR Technology Revenue Surges 197% in Q3 as Battery Sales Nearly Quadruple

November 10, 2026
Aerospace & Defense

Rocket Lab Q3 Revenue Surges 73% to $268 Million, Beating Wall Street Expectations

November 9, 2026
Artificial Intelligence

IonQ Shares Climb as Company Expands Government Reach Through Carahsoft Partnership

November 9, 2026
Aerospace & Defense

AST SpaceMobile and Rakuten Launch Joint Venture Backed by $1 Billion in Japanese Government Funding

November 9, 2026
Stoxpo

Follow us on social media:

Highlights

  • Anthropic Leveraged ETFs: What GraniteShares’ AIL and ANS Offer Traders
  • KULR Technology Secures $14.8 Million Purchase Order for Advanced Energy Storage Systems
  • SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results
  • Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers
  • D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

Anthropic Leveraged ETFs: What GraniteShares’ AIL and ANS Offer Traders

November 20, 2026

KULR Technology Secures $14.8 Million Purchase Order for Advanced Energy Storage Systems

November 18, 2026
chemistry-2

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

November 17, 2026
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.